Literature DB >> 22684520

Mast cells impair the development of protective anti-tumor immunity.

Anna Wasiuk1, Dyana K Dalton, William L Schpero, Radu V Stan, Jose R Conejo-Garcia, Randolph J Noelle.   

Abstract

Mast cells have emerged as critical intermediaries in the regulation of peripheral tolerance. Their presence in many precancerous lesions and tumors is associated with a poor prognosis, suggesting mast cells may promote an immunosuppressive tumor microenvironment and impede the development of protective anti-tumor immunity. The studies presented herein investigate how mast cells influence tumor-specific T cell responses. Male MB49 tumor cells, expressing HY antigens, induce anti-tumor IFN-γ(+) T cell responses in female mice. However, normal female mice cannot control progressive MB49 tumor growth. In contrast, mast cell-deficient c-Kit(Wsh) (W(sh)) female mice controlled tumor growth and exhibited enhanced survival. The role of mast cells in curtailing the development of protective immunity was shown by increased mortality in mast cell-reconstituted W(sh) mice with tumors. Confirmation of enhanced immunity in female W(sh) mice was provided by (1) higher frequency of tumor-specific IFN-γ(+) CD8(+) T cells in tumor-draining lymph nodes compared with WT females and (2) significantly increased ratios of intratumoral CD4(+) and CD8(+) T effector cells relative to tumor cells in W(sh) mice compared to WT. These studies are the first to reveal that mast cells impair both regional adaptive immune responses and responses within the tumor microenvironment to diminish protective anti-tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684520      PMCID: PMC3808181          DOI: 10.1007/s00262-012-1276-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  48 in total

1.  Mast cell-dependent down-regulation of antigen-specific immune responses by mosquito bites.

Authors:  Nadya Depinay; Fériel Hacini; Walid Beghdadi; Roger Peronet; Salaheddine Mécheri
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

Review 2.  Immunomodulatory mast cells: negative, as well as positive, regulators of immunity.

Authors:  Stephen J Galli; Michele Grimbaldeston; Mindy Tsai
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

3.  Cell-cell cooperation at the T helper cell/mast cell immunological synapse.

Authors:  Nicolas Gaudenzio; Nicolas Espagnolle; Lennart T Mars; Roland Liblau; Salvatore Valitutti; Eric Espinosa
Journal:  Blood       Date:  2009-10-05       Impact factor: 22.113

4.  Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy.

Authors:  Anna Johansson; Stina Rudolfsson; Peter Hammarsten; Sofia Halin; Kristian Pietras; Jonathan Jones; Pär Stattin; Lars Egevad; Torvald Granfors; Pernilla Wikström; Anders Bergh
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

5.  Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.

Authors:  A Loskog; C Ninalga; T Hedlund; M Alimohammadi; P-U Malmström; T H Tötterman
Journal:  Lab Anim       Date:  2005-10       Impact factor: 2.471

6.  Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES.

Authors:  Mikako Aoki; Ruby Pawankar; Yayoi Niimi; Seiji Kawana
Journal:  Int Arch Allergy Immunol       Date:  2003-03       Impact factor: 2.749

7.  Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo.

Authors:  Michele A Grimbaldeston; Ching-Cheng Chen; Adrian M Piliponsky; Mindy Tsai; See-Ying Tam; Stephen J Galli
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

8.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Authors:  Rajeev K Shrimali; Zhiya Yu; Marc R Theoret; Dhanalakshmi Chinnasamy; Nicholas P Restifo; Steven A Rosenberg
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

9.  Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

Authors:  Feng-Chun Yang; David A Ingram; Shi Chen; Yuan Zhu; Jin Yuan; Xiaohong Li; Xianlin Yang; Scott Knowles; Whitney Horn; Yan Li; Shaobo Zhang; Yanzhu Yang; Saeed T Vakili; Menggang Yu; Dennis Burns; Kent Robertson; Gary Hutchins; Luis F Parada; D Wade Clapp
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

10.  Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model.

Authors:  Zhuoshun Yang; Biao Zhang; Dapeng Li; Meng Lv; Chunmei Huang; Guan-Xin Shen; Bo Huang
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

View more
  19 in total

1.  Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.

Authors:  Zheng Liu; Yu Zhu; Le Xu; Junyu Zhang; Huyang Xie; Hangcheng Fu; Quan Zhou; Yuan Chang; Bo Dai; Jiejie Xu
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Bone marrow mast cell density correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma.

Authors:  C A Pappa; G Tsirakis; M Devetzoglou; M Zafeiri; R Vyzoukaki; A Androvitsanea; A Xekalou; K Sfiridaki; M G Alexandrakis
Journal:  Tumour Biol       Date:  2014-02-23

3.  Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.

Authors:  C Visciano; F Liotti; N Prevete; G Cali'; R Franco; F Collina; A de Paulis; G Marone; M Santoro; R M Melillo
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

4.  Erosion of Transplantation Tolerance After Infection.

Authors:  J S Young; M D Daniels; M L Miller; T Wang; R Zhong; D Yin; M-L Alegre; A S Chong
Journal:  Am J Transplant       Date:  2016-07-13       Impact factor: 8.086

5.  Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Authors:  Naoto T Ueno; Savitri Krishnamurthy; Jennifer A Wargo; Elizabeth A Mittendorf; Sangeetha M Reddy; Alexandre Reuben; Souptik Barua; Hong Jiang; Shaojun Zhang; Linghua Wang; Vancheswaran Gopalakrishnan; Courtney W Hudgens; Michael T Tetzlaff; James M Reuben; Takahiro Tsujikawa; Lisa M Coussens; Khalida Wani; Yan He; Lily Villareal; Anita Wood; Arvind Rao; Wendy A Woodward
Journal:  Cancer Immunol Res       Date:  2019-05-01       Impact factor: 11.151

Review 6.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 7.  Emerging strategies for cancer immunoprevention.

Authors:  J C Roeser; S D Leach; F McAllister
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 8.  Mast Cells: A New Frontier for Cancer Immunotherapy.

Authors:  Jake N Lichterman; Sangeetha M Reddy
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

9.  Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation.

Authors:  Tom Groot Kormelink; Desmond G Powe; Sylvia A Kuijpers; Abulikemu Abudukelimu; Marcel H A M Fens; Ebel H E Pieters; Willemiek W Kassing van der Ven; Hany O Habashy; Ian O Ellis; Bart R Blokhuis; Marco Thio; Wim E Hennink; Gert Storm; Frank A Redegeld; Raymond M Schiffelers
Journal:  Oncotarget       Date:  2014-05-30

10.  VISTA Regulates the Development of Protective Antitumor Immunity.

Authors:  Isabelle Le Mercier; Wenna Chen; Janet L Lines; Maria Day; Jiannan Li; Petra Sergent; Randolph J Noelle; Li Wang
Journal:  Cancer Res       Date:  2014-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.